|
|
|
|
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions. Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia.
|
|
|
|
Partner with your doctor
for care you deserve.
|
|
|
|
Krystal and Chase, and their son Dallas, who lives with Glanzmann's thrombasthenia with resistance to platelets.
|
|
|
Every appointment with your care team is a chance to use your voice and share more about what's really happening—from bleeds to daily challenges.
|
|
Our resource page offers you tools to help you track symptoms, frame meaningful conversations with your doctor, and feel more confident about asking about at-home access to NovoSeven® RT.
|
|
|
|
|
Keep scrolling to learn more about how to contact an RBCL
|
|
|
| Important Safety Information for NovoSeven® RT? |
| What is the most important information I should know about NovoSeven® RT? |
| NovoSeven® RT may cause serious side effects, including: |
| • |
Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported |
|
| • |
Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function |
|
| • |
Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
Find support from your local Rare Blood Community Liaison (RBCL)
|
|
Your RBCL can help you:
|
|
|
Practice
how to start important conversations with your care team
|
|
|
Practice how to start important conversations with your care team
|
|
Learn
what to ask during appointments so you can self-advocate
|
|
|
Learn what to ask during appointments so you can self-advocate
|
|
Explore
available educational and support resources
|
|
|
Explore available educational and support resources
|
|
Connect
with others living with rare bleeding disorders
|
|
|
Connect with others living with rare bleeding disorders
|
|
|
|
|
Connect with your local RBCL to gain confidence on how to self-advocate and have a shared decision making conversation before your next doctor's appointment.
|
|
|
|
|
| What is NovoSeven® RT? |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: |
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions |
|
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
|
What is the most important information I should know about NovoSeven® RT? (cont’d)
|
|
NovoSeven® RT may cause serious side effects, including: (cont’d)
|
| • |
You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness
|
|
|
What should I tell my healthcare provider before using NovoSeven® RT?
|
| • |
Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
|
| |
| ◦ |
congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates) |
| ◦ |
are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding |
| ◦ |
history of heart or blood vessel diseases |
|
|
| • |
Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies
|
|
|
What are the possible side effects of NovoSeven® RT?
|
| • |
The most common and serious side effects are blood clots
|
|
| • |
Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction
|
|
| Please click here for Prescribing Information. |
|
NovoSeven® RT is a prescription medication.
|
|
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
|
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® RT is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2026 Novo Nordisk All rights reserved. US25NSVN00048 February 2026 |
 |
|
|
|
